標(biāo)題: Titlebook: Radiopharmaceutical Therapy; Lisa Bodei,Jason S. Lewis,Brian M. Zeglis Book 2023 The Editor(s) (if applicable) and The Author(s), under ex [打印本頁] 作者: 召集會議 時間: 2025-3-21 16:15
書目名稱Radiopharmaceutical Therapy影響因子(影響力)
作者: Volatile-Oils 時間: 2025-3-21 22:31 作者: RACE 時間: 2025-3-22 03:50
978-3-031-39772-1The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: 說笑 時間: 2025-3-22 04:52
Lisa Bodei,Jason S. Lewis,Brian M. ZeglisFirst book of its kind of to cover radiopharmaceutical therapy.Comprehensive and accessible introduction to a rapidly-growing field.Useful for a broad audience of scientists, researchers, physicians, 作者: 長矛 時間: 2025-3-22 09:07
The Production of Therapeutic Radionuclidesh the decay of long-lived radionuclides such as .U, .Th, and .U, upon which chemically distinct daughters can be separated for incorporation into radiopharmaceuticals. The rate of the production of a given radionuclide depends on the cross section of the nuclear reaction on the target material, the 作者: MOAT 時間: 2025-3-22 13:41 作者: 出血 時間: 2025-3-22 17:46 作者: 熱情贊揚(yáng) 時間: 2025-3-23 00:06 作者: Flatus 時間: 2025-3-23 05:23
Case Study #3: Antibody Fragments in Radiopharmaceutical Therapylity, unfavorable tissue distribution, and reduced binding affinity of radiolabeled antibody fragments have inhibited their widespread application in radiopharmaceutical therapy. In response, a great deal of effort has been dedicated to optimize the pharmacokinetics of antibody fragments (especially作者: 分解 時間: 2025-3-23 06:38 作者: Galactogogue 時間: 2025-3-23 11:06
Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapyata from the most important work in this field, the phase III NETTER-1 trial, which showed that the treatment of unresectable/metastatic progressive small bowel NETs with Lutathera. resulted in a significant improvement in progression-free survival (PFS) and overall survival (OS) compared with high-作者: 接合 時間: 2025-3-23 14:03 作者: Mettle 時間: 2025-3-23 21:02 作者: 形容詞詞尾 時間: 2025-3-24 01:44 作者: 包租車船 時間: 2025-3-24 02:39
Book 2023eview process for radiotherapeutics..This book is the first of its kind andis useful for a broad audience of scientists, researchers, physicians, and students across a range of fields, including biochemistry, cancer biology, nuclear medicine, radiology, and radiation oncology..作者: 盡管 時間: 2025-3-24 07:57 作者: VERT 時間: 2025-3-24 13:59
Ganesan Vaidyanathan,Yutian Feng,Michael R. Zalutsky作者: Femish 時間: 2025-3-24 15:05 作者: 性冷淡 時間: 2025-3-24 23:00
Nai-Kong V. Cheung,Kim Kramer,Shakeel Modak,Brian H. Kushner,Mahiuddin Ahmed,Brian Santich,Sarah Che作者: 生氣地 時間: 2025-3-24 23:34 作者: 慢慢流出 時間: 2025-3-25 03:50
Ryan A. Davis,Tanushree Ganguly,Sven H. Hausner,Julie L. Sutcliffe作者: d-limonene 時間: 2025-3-25 10:15 作者: Delectable 時間: 2025-3-25 15:04 作者: 血統(tǒng) 時間: 2025-3-25 17:51 作者: 男生戴手銬 時間: 2025-3-25 22:23 作者: OMIT 時間: 2025-3-26 01:50 作者: 抱負(fù) 時間: 2025-3-26 06:46 作者: ANA 時間: 2025-3-26 11:15
The Nuclear Chemistry of Therapeutic Radionuclides radionuclides, while Chaps. . and . focus on the chemical behavior (and thus electrons) of these elements. This chapter first discusses the radioactive emissions that currently dominate the field—beta-electrons and alpha-particles—including their origin in primary transformation processes and their作者: eczema 時間: 2025-3-26 15:32
The Production of Therapeutic Radionuclidesons and the decay properties of radionuclides can guide the methods for the production of these important tools. Nuclear reactions can be induced with neutrons, charged particles, or photons in both nuclear reactors and particle accelerators. Most therapeutic radionuclides are produced in nuclear re作者: Judicious 時間: 2025-3-26 20:51 作者: 擴(kuò)張 時間: 2025-3-27 01:01 作者: reperfusion 時間: 2025-3-27 01:33 作者: 不給啤 時間: 2025-3-27 07:21
Dosimetry in Radiopharmaceutical Therapyhealthy tissue. The utility and efficacy of a targeted radiotherapeutic procedure arise from the interplay between the physiological distribution of a radiopharmaceutical, the emitted particles of the associated radionuclide, the subject’s anatomy, and radiobiologic factors. The characterization of 作者: scotoma 時間: 2025-3-27 11:29 作者: chronicle 時間: 2025-3-27 16:02
Case Study #1: Alpha Particle Therapy of Leukemia Using 225Ac-Lintuzumabessed on acute myeloid leukemia (AML) cells. The name “actinium” is derived from the Greek . meaning “ray” or “beam,” and the decay of each actinium-225 atom produces 4 alpha (α) particles during the cascade to stable .Bi. Lintuzumab (HuM195) is a humanized immunoglobulin G (IgG) that was selected f作者: Exterior 時間: 2025-3-27 18:30
Case Study #2: Disialoganglioside GD2 as a Target for Radiopharmaceutical Therapycluding neuroblastoma, osteosarcoma, soft tissue sarcomas, and others. Dinutuximab (chimeric 14.18) and naxitamab (humanized 3F8 or hu3F8) are Food and Drug Administration (FDA)-approved monoclonal antibodies (mAb) that are specific for the penta-oligosaccharide epitope in GD2. Immuno-oncology, radi作者: 很像弓] 時間: 2025-3-27 22:42 作者: entrance 時間: 2025-3-28 05:08 作者: 受人支配 時間: 2025-3-28 08:54
Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapyolabelled peptide designed to target receptors overexpressed on tumor cells. The most frequently employed target for PRRT in clinical practice is the somatostatin receptor (SSTR), which is overexpressed on a range of tumor cells including neuroendocrine tumors (NETs). In this case study, we describe作者: 打算 時間: 2025-3-28 13:22
Case Study #5: CXCR4-Targeted Radiotherapeuticsoendocrine neoplasms or common cancers such as prostate carcinoma. In recent years, RPT has been expanded towards the treatment of hematological neoplasms, in particular by targeting C-X-C motif chemokine receptor 4 (CXCR4). To this end, the most comprehensively evaluated theranostic pair is compose作者: 車床 時間: 2025-3-28 15:58
Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutch as .Lu-labeled agonists of somatostatin receptor subtype 2 (SST.) (e.g., [.Lu]Lu-DOTA-TOC and [.Lu]Lu-DOTA-TATE (Lutathera.)). SST. are highly overexpressed in neuroendocrine tumors (NETs), which are most commonly found in the stomach, intestines, pancreas, and lungs. Until recently, it was thoug作者: 節(jié)約 時間: 2025-3-28 18:50
Small Molecules as Vectors for Radiopharmaceutical Therapyth metastatic, castration-resistant prostate cancer whose tumors express prostate-specific membrane antigen (PSMA; [.Lu]Lu-PSMA-617), and patients with metastatic or unresectable neuroblastoma, pheochromocytoma, or paraganglioma ([.I]MIBG). Numerous lines of inquiry continue to be pursued with small作者: PHON 時間: 2025-3-29 02:19 作者: 不公開 時間: 2025-3-29 06:41 作者: chalice 時間: 2025-3-29 08:31
The Nuclear Chemistry of Therapeutic Radionuclides transformation processes and can be helpful for the molecular imaging of radionuclides and the radiotherapeutics carrying them. Next, the most relevant (and some potential) therapeutic radionuclides are identified. Finally, the chapter evaluates the relevant production pathways of therapeutic radionuclides.作者: interference 時間: 2025-3-29 14:17
The Radiobiology of Radiopharmaceutical Therapy: The Input of Imaging and Radiomics of radiobiology should no longer be restricted to preclinical experiments and should be extended to clinical research. The implementation of clinical radiobiology requires the analysis of patient samples and the use of non-invasive imaging approaches to extract tumour features that are indicative of response to RPT.作者: cyanosis 時間: 2025-3-29 18:59 作者: forthy 時間: 2025-3-29 21:42
Antibodies as Vectors for Radiopharmaceutical Therapy of the results for each of the steps. At the end of this chapter, those studying RPT should have a good understanding of the strengths and limitations of radioimmunoconjugates as therapeutic tools in the clinic.作者: cultivated 時間: 2025-3-30 03:58
Introduction: The Case for Radiopharmaceutical Therapyelopment of new approaches to RPT is possible with new targets and the application of novel radionuclides. In the end, the forward progress of RPT is predicated on both well-designed, step-wise, multicenter prospective clinical trials and specialized endoradiotherapy training programs.作者: dictator 時間: 2025-3-30 06:12
Dosimetry in Radiopharmaceutical Therapythis multifactorial paradigm is encapsulated in the field of internal dosimetry. Through dosimetry, we quantify the distribution and strength of the intervention in terms of radiation dose deposition. This information supports clinicians in predicting and optimizing treatment outcomes.作者: 致詞 時間: 2025-3-30 08:26 作者: Gene408 時間: 2025-3-30 14:00 作者: Hirsutism 時間: 2025-3-30 17:13 作者: 細(xì)頸瓶 時間: 2025-3-30 23:46
Net Promoter Score and Its Successful Application,eve. So, this is not a chapter about easy paths to success, but about the lessons learnt (often from failure) and the potential unrealized of what is still a foundational business concept: it is your loyal customers that grow your business.作者: 值得尊敬 時間: 2025-3-31 04:52 作者: 成份 時間: 2025-3-31 08:23 作者: micronized 時間: 2025-3-31 12:17 作者: Contracture 時間: 2025-3-31 17:02 作者: Odyssey 時間: 2025-3-31 18:50
range of topics is covered including:.·???????? Business Administration & Economic Environment .·???????? Technological & Organizational Innovation.·???????? Logistics & Supply Chain Management.·???????? 978-1-4471-7090-7978-1-4471-5349-8作者: Dissonance 時間: 2025-4-1 01:06 作者: 芭蕾舞女演員 時間: 2025-4-1 04:36 作者: 成績上升 時間: 2025-4-1 08:54
